Health
CEPI to Invest $66 Million to Boost Clover’s COVID-19 Vaccine Trial – The New York Times
China’s Clover Biopharmaceuticals Inc has received $66 million in investment from the Coalition for Epidemic Preparedness Innovation (CEPI) to bolster the testing of a potential COVID-19 vaccine, the global epidemic response group said on Wednesday.
(Reuters) – China’s Clover Biopharmaceuticals Inc has received $66 million in investment from the Coalition for Epidemic Preparedness Innovation (CEPI) to bolster the testing of a potential COVID-19 vaccine, the global epidemic response group said on Wednesday.
Last month, Clover became the sixth Chinese developer of a potential COVID-19 vaccine to move into human trials by launching a study in Australia to test its vaccine with boosters.
The foundation said the funding aims to help produce hundreds of millions of doses of the potential vaccine per year and if the early stage trials are successful, it expects to provide “significant” additional support.
On successful completion of trials, the vaccine will be made available globally, it said.
CEPI’s latest investment in Clover comes on top of an initial $3.5 million in funding when they announced a partnership in April.
-
Business16 hours agoWhat is Macquarie’s price target for Evolution Mining shares after its FY25 result?
-
Noosa News24 hours agoSXSW Sydney Unlocked – Concrete Playground
-
Noosa News16 hours agoAttorney-General appeals ‘plainly unjust’ sentence for teen who caused triple fatal crash
-
Business19 hours ago4 reasons to buy ANZ shares today